All In Biotech

Drug Trial Radar · NCT07697560

Safety, Tolerability, and PK of AH-008 Following Single Ascending Dose in Healthy Subjects

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AH-008 Following Single Ascending Dose Administration in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Jun 10, 2026

Primary completion

Sep 25, 2026

Study completion Sep 25, 2026

Sponsor

Lead sponsor
AnHorn Medicines Co. Ltd.Industry
Sponsor type
Industry
First posted
Jul 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, first-in-human (FIH), randomized, double-blind, placebo-controlled, parallel-group, single ascending dose (SAD) study to evaluate the safety, tolerability, and pharmacokinetics of AH-008 administered as a single intravenous infusion in healthy adult subjects. Four sequential dose cohorts will be evaluated, each with sentinel dosing and SRC-reviewed dose escalation.

Conditions

  • Chemotherapy-induced Peripheral Neuropathy (CIPN)

Interventions

  • AH-008 for Injection, 150 mgDrug

    Lyophilized powder

  • AH-008 for Injection, PlaceboDrug

    Lyophilized powder

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events (TEAEs)Time frame: From Baseline (Day -1) through Day 3 (48 hours after dosing)
  2. Incidence of Clinically Significant Vital Sign AbnormalitiesTime frame: From Baseline (Day -1) through Day 3 (48 hours after dosing)
  3. Incidence of Clinically Significant 12-Lead ECG AbnormalitiesTime frame: From Baseline (Day -1) through Day 3 (48 hours after dosing)
  4. Incidence of Clinically Significant Clinical Laboratory AbnormalitiesTime frame: From Baseline (Day -1) through Day 3 (48 hours after dosing)
  5. Incidence of Subjects with Infusion Site ReactionsTime frame: From Baseline (Day -1) through Day 3 (48 hours after dosing)
  6. Pharmacokinetic characterization of maximum observed plasma concentration (Cmax) of AH-008Time frame: From Baseline (Day -1) through Day 3 (48 hours after dosing)
  7. Pharmacokinetic characterization of time to maximum observed plasma concentration (Tmax) of AH-008Time frame: From Baseline (Day -1) through Day 3 (48 hours after dosing)
  8. Pharmacokinetic characterization of area under the plasma concentration-time curve (AUC) of AH-008Time frame: From Baseline (Day -1) through Day 3 (48 hours after dosing)
  9. Pharmacokinetic characterization of terminal elimination half-life (t½) of AH-008Time frame: From Baseline (Day -1) through Day 3 (48 hours after dosing)
  10. Pharmacokinetic characterization of cumulative amount of AH-008 excreted in urine (Ae0-t)Time frame: From Baseline (Day -1) through Day 3 (48 hours after dosing)
  11. Pharmacokinetic characterization of urine recovery rate of AH-008 (Ae%)Time frame: From Baseline (Day -1) through Day 3 (48 hours after dosing)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ICON Clinial Research Unit

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.